Single Blinded First CMC Osteoarthritis Treatment

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Single blinded PRP vs. Corticosteroid vs. Placebo (normal saline) intra-articular injection for basal joint arthritis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kettering Health Network

Criteria

Inclusion Criteria:

• Stage 1-3 osteoarthritis of the basal joint

Exclusion Criteria:

• Patients with Stage 4 1st carpometacarpal joint arthritis as described by Eaton

• Patients who have received a corticosteroid injection in the last year to the 1st CMC joint on the proposed study side

• Patients who have scaphotriquetral, radioscaphoid, or scaphotrapezial osteoarthritis

• Patients who have concurrent DeQuervain's tenosynovitis or intersection syndrome or have been treated for either of these in the last 3 months

• Patients undergoing evaluation of cervical radiculopathy

• Patients with fibromyalgia or inflammatory rheumatic disease

• Patients with Pressier disease, Kienbock's, or avascular necrosis of the scaphoid

• Patients with any history of primary or secondary bone tumor

• Patients that are pregnant or terminally ill